https://scholars.lib.ntu.edu.tw/handle/123456789/494609
標題: | Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | 作者: | Wong N.S Anderson B.O Khoo K.S Ang P.T Yip C.H YEN-SHEN LU Voravud N Shao Z.-M Pritchard K.I. |
公開日期: | 2009 | 卷: | 10 | 期: | 11 | 起(迄)頁: | 1077-1085 | 來源出版物: | The Lancet Oncology | 摘要: | Patients with breast cancer positive for human epidermal growth-factor receptor type 2 (HER2) are an important subgroup for consideration in the Asian context. Rationally designed, anti-HER2 targeted agents that can substantially improve treatment outcomes have become commercially available, but are still too costly for some groups in developed countries and for underdeveloped and developing nations. This review discusses the available evidence for optimum management of HER2-positive early and advanced breast cancer, and how this evidence can be applied to Asian countries with different levels of health-care resources and economic development-using framework provided by the Breast Health Global Initiative. We provide a brief overview of HER2 testing and discuss management of early and advanced HER2-positive breast cancer, and formulate a consensus statement for the management of breast cancer in the context of basic, limited, enhanced, and maximum health-care resource availability. ? 2009 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-71549153340&doi=10.1016%2fS1470-2045%2809%2970230-X&partnerID=40&md5=fd976203add1ba1e9d81d5158adf17f4 https://scholars.lib.ntu.edu.tw/handle/123456789/494609 |
ISSN: | 1470-2045 | DOI: | 10.1016/S1470-2045(09)70230-X | SDG/關鍵字: | anastrozole; aromatase inhibitor; capecitabine; carboplatin; cyclophosphamide; docetaxel; doxorubicin; epidermal growth factor receptor 2; epirubicin; everolimus; fluorouracil; lapatinib; letrozole; methotrexate; navelbine; paclitaxel; tamoxifen; tanespimycin; trastuzumab; adjuvant therapy; Asia; breast cancer; cancer survival; clinical trial; congestive heart failure; drug cost; drug response; fluorescence in situ hybridization; gene amplification; heart death; human; immunohistochemistry; leukemia; multiple cycle treatment; ovariectomy; postmenopause; practice guideline; priority journal; resource allocation; review; Antineoplastic Agents; Asia; Breast Neoplasms; Congresses as Topic; Developing Countries; Drug Costs; Early Detection of Cancer; Evidence-Based Medicine; Female; Guideline Adherence; Health Care Costs; Health Services Accessibility; Healthcare Disparities; Humans; Medical Oncology; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Receptor, erbB-2; Survival Analysis; Time Factors; Tumor Markers, Biological |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。